澳股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

TELIX PHARMACEUTICALS LTD

13.650

+0.7305.65%

成交量：239.43萬

成交額：3,199.98萬

市值：46.24億

市盈率：-445.40

高：13.650

開：12.850

低：12.770

收：12.920

52周最高：29.640

52周最低：8.260

股本：3.39億

流通股本：2.75億

量比：0.67

換手率：0.87%

股息：- -

股息率：- -

每股收益(TTM):-0.031

每股收益(LYR):-0.031

淨資產收益率：-1.85%

總資產收益率：1.15%

市淨率：7.66

市盈率(LYR):-445.41

資料載入中...

總覽公司新聞資訊公告

Telix Pharmaceuticals Ltd 向美國FDA重新提交腦癌成像候選藥物TLX101-PX（Pixclara™）新藥申請

Telix實現2025財年營收8.04億美元（12億澳元）目標，Gozellix上市加速增長

BUZZ-澳大利亞泰利克斯製藥公司因中國接受新藥申請而上漲

精準醫療投資組合更新：Illuccix中國三期研究及Tlx101-Cdx和Tlx250-Cdx FDA重新提交

Thor Medical與Telix Pharmaceuticals簽署戰略供應協議，提供銩228

Holzer & Holzer - 起訴指控被告對Telix的業務、運營等做出實質性虛假陳述

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"老虎國際,美股交易,港股交易,交易美股,股票信息,股價,美股行情,美股打新,港股打新,IPO打新,購買美股,全球投資","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/TLX.AU/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental","symbol":"TLX.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"TLX.AU\",,,,,undefined,":{"symbol":"TLX.AU","market":"AU","secType":"STK","nameCN":"TELIX PHARMACEUTICALS LTD","latestPrice":13.65,"timestamp":1774588320000,"preClose":12.92,"halted":0,"volume":2394329,"delay":0,"changeRate":0.056501547987616134,"nameEN":"TELIX PHARMACEUTICALS LTD","floatShares":275410996,"shares":338721355,"eps":-0.03064633260711692,"marketStatus":"休市中","change":0.73,"latestTime":"03-27 16:12:00 AEDT","open":12.85,"high":13.65,"low":12.77,"amount":31999810,"amplitude":0.068111,"askPrice":13.68,"askSize":1250,"bidPrice":13.55,"bidSize":6000,"shortable":3,"etf":0,"ttmEps":-0.03064633260711692,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":0,"beginTime":1774825200000},"marketStatusCode":7,"adr":0,"exchange":"ASX","adjPreClose":12.92,"openAndCloseTimeList":[[1774566000000,1774587600000]],"volumeRatio":0.6723549515116395,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"TLX.AU","preClose":12.92,"auctionPrice":13.68,"auctionVolume":256532,"auction":3,"marketStatus":"盘后竞价","timestamp":1774588215610}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"TLX.AU\",,,,,undefined,":{"symbol":"TLX.AU","floatShares":275410996,"roa":"1.15%","roe":"-1.85%","lyrEps":-0.030646,"volumeRatio":0.6723549515116395,"shares":338721355,"dividePrice":0,"high":13.65,"amplitude":0.068111,"preClose":12.92,"low":12.77,"week52Low":8.26,"pbRate":"7.66","psRate":"3.96","week52High":29.64,"institutionHeld":0,"latestPrice":13.65,"committee":0.655172,"eps":-0.03064633260711692,"divideRate":0,"volume":2394329,"delay":0,"ttmEps":-0.03064633260711692,"open":12.85,"prevYearClose":11.2,"prevWeekClose":12.75,"prevMonthClose":10,"prevQuarterClose":11.2,"fiveDayClose":12.75,"twentyDayClose":10,"sixtyDayClose":11.2},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/TLX.AU\",params:#limit:5,,,undefined,":[{"date":"2026-02-19","symbol":"TLX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1771455600000,"name":null,"time":"","dateTimestamp":1771419600000,"actualEps":null},{"date":"2026-01-19","symbol":"TLX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1768777200000,"name":null,"time":"","dateTimestamp":1768741200000,"actualEps":null},{"date":"2025-08-21","symbol":"TLX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1755734400000,"name":null,"time":"","dateTimestamp":1755698400000,"actualEps":null},{"date":"2025-02-19","symbol":"TLX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1739919600000,"name":null,"time":"","dateTimestamp":1739883600000,"actualEps":null},{"date":"2024-08-22","symbol":"TLX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1724284800000,"name":null,"time":"","dateTimestamp":1724248800000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"TLX.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"TLX.AU\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1116737586","title":"Telix Pharmaceuticals Ltd 向美國FDA重新提交腦癌成像候選藥物TLX101-PX（Pixclara™）新藥申請","url":"https://stock-news.laohu8.com/highlight/detail?id=1116737586","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1116737586?lang=zh_tw&edition=fundamental","pubTime":"2026-03-16 05:20","pubTimestamp":1773609615,"startTime":"0","endTime":"0","summary":"澳大利亚生物技术公司Telix Pharmaceuticals Ltd已正式向美国食品药品监督管理局重新递交了其脑癌成像候选药物TLX101-PX的新药申请。此次提交标志着该创新型诊断工具在获批道路上迈出关键一步。TLX101-PX是一种基于放射性示踪剂的成像剂，专门设计用于精准检测脑肿瘤病灶。公司此次重新提交的申请材料包含最新临床数据，旨在进一步验证Pixclara在复杂脑癌病例中的诊断效能。若获批准，该产品将成为脑癌诊疗领域的重要突破，为全球神经肿瘤患者提供更精准的诊疗方案。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TLX.AU","BK7067"],"gpt_icon":0},{"id":"1167408007","title":"Telix實現2025財年營收8.04億美元（12億澳元）目標，Gozellix上市加速增長","url":"https://stock-news.laohu8.com/highlight/detail?id=1167408007","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1167408007?lang=zh_tw&edition=fundamental","pubTime":"2026-01-20 20:07","pubTimestamp":1768910869,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals Ltd宣布达成2025财年业绩指引，实现营收8.04亿美元。公司同时推出新型放射性药物Gozellix，标志着其肿瘤靶向治疗产品线的重大拓展。这一突破性进展不仅巩固了Telix在核医学领域的领先地位，更为全球癌症患者提供了更精准的治疗选择。随着Gozellix的正式商业化，Telix将同步启动全球市场推广计划。Telix首席执行官表示，此次双里程碑的达成得益于公司持续的技术创新与全球化战略布局。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","TLX.AU"],"gpt_icon":0},{"id":"2604055151","title":"BUZZ-澳大利亞泰利克斯製藥公司因中國接受新藥申請而上漲","url":"https://stock-news.laohu8.com/highlight/detail?id=2604055151","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604055151?lang=zh_tw&edition=fundamental","pubTime":"2026-01-20 08:39","pubTimestamp":1768869597,"startTime":"0","endTime":"0","summary":"1月20日 - ** 澳大利亚泰利克斯制药公司TLX.AX股价上涨6.3%至11.99澳元，创下近两个月来最大盘中涨幅。(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260120:nL4S3YL01L:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","TNLX","00512","BK4157","TLX.AU","BK7067"],"gpt_icon":0},{"id":"1170607192","title":"精準醫療投資組合更新：Illuccix中國三期研究及Tlx101-Cdx和Tlx250-Cdx FDA重新提交","url":"https://stock-news.laohu8.com/highlight/detail?id=1170607192","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1170607192?lang=zh_tw&edition=fundamental","pubTime":"2025-12-22 05:40","pubTimestamp":1766353209,"startTime":"0","endTime":"0","summary":"精准医疗投资组合更新：Illuccix中国三期研究及Tlx101-Cdx和Tlx250-Cdx FDA重新提交","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TLX.AU","BK7067"],"gpt_icon":0},{"id":"1108683421","title":"Thor Medical與Telix Pharmaceuticals簽署戰略供應協議，提供銩228","url":"https://stock-news.laohu8.com/highlight/detail?id=1108683421","media":"投资观察","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1108683421?lang=zh_tw&edition=fundamental","pubTime":"2025-11-20 00:51","pubTimestamp":1763571104,"startTime":"0","endTime":"0","summary":"11月6日 - Thor Medical ASA宣布与Telix Pharmaceuticals达成战略供应协议，将在未来五年内向Telix供应铥228。从2026年第三季度起，铥228将从AlphaOne基地开始供给。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","TLX.AU"],"gpt_icon":0},{"id":"1102089575","title":"Holzer & Holzer - 起訴指控被告對Telix的業務、運營等做出實質性虛假陳述","url":"https://stock-news.laohu8.com/highlight/detail?id=1102089575","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1102089575?lang=zh_tw&edition=fundamental","pubTime":"2025-11-13 00:15","pubTimestamp":1762964112,"startTime":"0","endTime":"0","summary":"Holzer & Holzer - 起诉指控被告对Telix的业务、运营等做出实质性虚假陈述","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","TLX.AU"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":6,"code":"91000000","status":"200"}]}}